RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • February 22nd, 2013 • Intercept Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledFebruary 22nd, 2013 Company Industry JurisdictionThis Amendment No. 2 to Research and Development Agreement, dated February 15, 2013, is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, with its registered office at 18 Desbrosses Street, New York, NY 10013, USA (“INTERCEPT”) on the one hand and TES Pharma Srl, a corporation organized and existing under the laws of Italy, with its registered office at Via Settevalli 556, 06129, Perugia, Italy (“TES”) on the other hand.
AMENDMENT NO. 2 TOConsulting and Intellectual Property Agreement • February 22nd, 2013 • Intercept Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledFebruary 22nd, 2013 Company Industry JurisdictionThis Amendment No. 2 to Consulting and Intellectual Property (“IP”) Agreement (this “Amendment”), dated February 15, 2013, is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, with its registered office at 18 Desbrosses Street, New York, NY 10013, USA (“INTERCEPT”) on the one hand and ROBERTO PELLICCIARI (“Consultant”), residing at Via U. Rocchi, 60, Perugia, Italy 06123, on the other hand:
AMENDMENT N°2 TO PRODUCT RESEARCH, DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (this “Amendment”)Product Research, Development, License and Commercialization Agreement • February 22nd, 2013 • Intercept Pharmaceuticals Inc • Pharmaceutical preparations
Contract Type FiledFebruary 22nd, 2013 Company Industrya corporation organized and existing under the laws of Delaware, with registered office at 18 Desbrosses Street, New York, NY 10013, USA